Lack of National Adoption of Evidence-Based Treatment for Resectable Gastric Adenocarcinoma

BACKGROUND: Level 1 evidence for multimodal treatment of resectable gastric adenocarcinoma from the Intergroup 0116 (2001) and MAGIC (2006) trials demonstrated survival benefit of adjuvant chemoradiation (CRT) and perioperative chemotherapy, respectively. We evaluated the adoption of evidence-based...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Tiffany C., Wima, Koffi, Morris, Mackenzie C., Johnston, Michael E., Shah, Shimul A., Ahmad, Syed A., Patel, Sameer H., Wilson, Gregory C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
SSAT Quick Shot Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670838/
https://www.ncbi.nlm.nih.gov/pubmed/33201456
http://dx.doi.org/10.1007/s11605-020-04868-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670838/
https://www.ncbi.nlm.nih.gov/pubmed/33201456
http://dx.doi.org/10.1007/s11605-020-04868-0

Ejemplares similares